Muscarinic Acetylcholine Receptor Market Size, Share & Industry Analysis, By Product Type (M1, M4, M5, Others), By Application Type (Alzheimers Disease, Chronic Obstructive Pulmonary Disease (COPD), Psychiatric Disorders, Attention Deficit Hyperactivity Disorder, Others) Others and Regional Forecast, 2024-2032

Muscarinic acetylcholine receptor are metabotropic receptors that, depending on their coupling to G-protein α-subunits, can excite or inhibit postsynaptic neurons. These receptors are the member of G-protein-coupled receptor’s family, specifically class A receptors. These receptors are triggered in the presence of acetylcholine which is released from the postganglionic fibers of the nervous system. Acetylcholine functions as neurotransmitters in the central nervous system and the peripheral nervous system. Acetylcholine causes excitatory actions in the central nervous system by activating muscles in the peripheral nervous system.

Increasing prevalence of neurological disorders across the globe is one of the major factor augmenting muscarinic acetylcholine receptor market growth during the forecast period. Neurological disorders such as, alzheimers disease, memory impairment and other psychiatric disorders can be treated with the application of muscarinic acetylcholine receptors. Hence, increasing prevalence of such diseases will significanlty propel market growth. Additionally, these receptors can be used for the treatment other chronic diseases as well. For instance, chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disorder characterized by poor airflow and long-term breathing problems, which can be treated with the use of such receptors. Hence, increasing prevalence of neurological disorders coupled with growing number of applications pertaining to muscarinic acetylcholine receptors will considerably support market growth across the forecast period.

However, presence of stringent government regulatory policies for the approval of such receptors, along with lack of awareness among the population are factors limiting the market growth of muscarinic acetylcholine receptors.

Market Segmentation:

By product type, the market is segmented into M1, M4, M5 and others. Based on application type, the market is segmented into Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), memory impairment, psychiatric disorders, attention deficit hyperactivity disorder and others.

From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Players Covered:

The major companies in the global muscarinic acetylcholine receptor market report includes Anavex Life Sciences Corp., AstraZeneca, Sosei Heptares., Karuna Therapeutics., NeuroHealing Pharmaceuticals Inc., Sumitomo Dainippon Pharma Co., Ltd., and others.

Key Insights

• New Advancements in the R&D Activities for Muscarinic Acetylcholine Receptor


• Prevalence Data on Neurological Disorders, Key Countries, 2018


• Regulatory Scenario, Key Countries, 2018


• New Product Launch, Key Players

Regional Analysis:

The global muscarinic acetylcholine receptor market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe is expected to hold considerable shares in the global muscarinic acetylcholine receptor market in 2018, owing to rise in number of applications pertaining to such receptors coupled with growing number of market players operating in the region. However, increasing patient pool suffering from chronic diseases along with growing awareness among the population of the Asia Pacific countries are anticipated to fuel the demand of muscarinic acetylcholine receptor in the region. Also, focus on R&D activities with an aim to manufacture enhanced treatment solutions through these receptors will further augment market growth. 

Segmentation

Muscarinic Acetylcholine Receptor Industry Developments

• In November 2019, Karuna Therapeutics, announced the successful phase III clinical trial results and approval of KarXT for acute psychosis in patients with schizophrenia. KarXT is a muscarinic acetylcholine receptor (mAChR) agonist at M1 and M4. Such approvals will assist the company to expand its product portfolio as well as serve a broader customer base.


• November 2017, Sosei Heptares announced the amendment of global R&D and commercialisation partnership with Allergan to expand clinical development of HTL0018318 in major dementia indication. HTL0018318 is a novel muscarinic M1 receptor agonist in clinical development as a potential treatment for cognitive impairment in Alzheimer’s disease.